Filter By:

Article Type
  • The widespread use of screening for circulating anti-neutrophil cytoplasmic autoantibodies (ANCA) in the diagnosis of ANCA-associated vasculitis has resulted in an increased occurrence of false-positive results and greater difficulty in the interpretation of such test results. Therefore, a rational strategy for ANCA testing is needed. The main problems with ANCA testing are discussed in this Viewpoint and some practical guidelines are given.

    • Elena Csernok
    • Peter Lamprecht
    • Wolfgang L Gross
  • Evidence-based medicine and, primarily, data from randomized controlled clinical trials are continually regarded as the only valid sources for all clinical knowledge. This Viewpoint discusses the merits of 'practice-based evidence' and how this important information is currently undervalued in the clinical community.

    • Theodore Pincus
    • Tuulikki Sokka
  • There has been significant progress in the development of biological markers to assess joint and tissue damage in osteoarthritis. In this Viewpoint, Patrick Garnero discusses the developments in this field and how they will affect the future management of patients with osteoarthritis.

    • Patrick Garnero
  • Choosing the correct management strategy for patients with rheumatoid arthritis in order to achieve the best possible outcome is a challenge to all rheumatologists. This Viewpoint considers current progress in the field of outcomes research in rheumatoid arthritis, along with future prospects of predicting individual patient response to therapy.

    • Josef S Smolen
    • Daniel Aletaha
  • The standards of 'state of the art' in-office imaging are rapidly changing. This Viewpoint assesses the imaging techniques available for in-office use and highlights the obstacles that need to be overcome in this field in order for clinicians to have easy access to the right data in order to provide the best possible care.

    • John T Sharp
  • There is increasing evidence that treatment in the early stages of rheumatoid arthritis can significantly increase the potential for positive patient outcome and prevention of irreversible damage. This Viewpoint considers the evidence that supports aggressive treatment for early rheumatoid arthritis and investigates the available treatment options.

    • Tom WJ Huizinga
    • Robert BM Landewé
  • Diagnosis of early rheumatoid arthritis can be significantly hastened by the screening for serological markers such as autoantibodies. This Viewpoint discusses the merits of this new field of serological screening, focusing on the anti-cyclic citrullinated peptide tests and their value as diagnostic tools for rheumatoid arthritis.

    • Walther J van Venrooij
    • Leo BA van de Putte